Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;17(5):710-6.
doi: 10.1016/j.bbmt.2010.08.017. Epub 2010 Oct 14.

Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants

Melhem Solh  1 , Claudio Brunstein, Shanna Morgan, Daniel Weisdorf
Affiliations

Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants

Melhem Solh et al. Biol Blood Marrow Transplant. 2011 May.

Abstract

Allogeneic hematopoietic cell transplantation (HCT) recipients have substantial transfusion requirements. Factors associated with increased transfusions and the extent of blood product use in umbilical cord blood (UCB) recipients are uncertain. We reviewed blood product use in 229 consecutive adult recipients of allogeneic HCT at the University of Minnesota: 147 with leukemia, 82 lymphoma or myeloma; 58% received unrelated UCB and 43% sibling donor peripheral blood stem cell (PBSC) grafts. Although neutrophil recovery was prompt (UCB median 17, range: 2-45 days, and PBSC 14, range: 3-34 days), only 135 of 229 (59% cumulative incidence) achieved red blood cell (RBC) independence and 157 (69%) achieved platelet independence by 6 months. Time to platelet independence was prolonged in UCB recipients (median UCB 41 versus PBSC 14 days) and in patients who had received a prior transplant (median 48 versus 32 days). Patients who received UCB grafts required more RBC through day 60 post-HCT (mean UCB 7.8 (95% confidence interval [CI] 6.7-8.9) versus PBSC 5.2 (3.7-6.7) transfusions, P = .04), and more platelet transfusions (mean 25.2 (95% CI 22.1-28.2) versus 12.9 (9.4-16.4), P < .01) compared to PBSC recipients. Patients receiving myeloablative (MA) conditioning required more RBC and platelet transfusions during the first 2 months post-HCT compared to reduced-intensity conditioning (RIC) (7.4 versus 6.2, P = .30 for RBC; 23.2 versus 17.5, P = .07 for platelets). Despite prompt neutrophil engraftment, UCB recipients had delayed platelet recovery as well as more prolonged and costly blood product requirements. Enhanced approaches to accelerate multilineage engraftment could limit the transfusion-associated morbidity and costs accompanying UCB allotransplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time to RBC and Platelet independence In leukemia patients, shown is the cumulative incidence of the time to transfusion independence (untransfused Hb>8 g/dl; PLT >20,000/μl) in recipients of UCB or sibling donor PBSC grafts.
Figure 2
Figure 2
Marginal Mean of Platelet (A) and RBC transfusion (B) over time Shown are the marginal mean of cumulative PLT (panel A) and RBC (B) transfusions over the first 6 months post HCT for patients with leukemia. UCB recipients have significantly greater mean PLT (p<0.01) and RBC (p=0.02) transfusion needs compared to PBSC.
See this image and copyright information in PMC

References

    1. Hiemenz JW. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2009;46(3):289–312. - PubMed
    1. Osterwalder B, Gratwohl A, Reusser P, Tichelli A, Speck B. Hematological support in patients undergoing allogenetic bone marrow transplantation. Recent Results Cancer Res. 1988;108:44–52. - PubMed
    1. Pihlstedt P, Paulin T, Sundberg B, Nilsson B, Ringden O. Blood transfusion in marrow graft recipients. Ann Hematol. 1992;65(2):66–70. - PubMed
    1. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 362(7):600–13. - PMC - PubMed
    1. Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringden O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 × 10(9) per L versus 30 × 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion. 2005;45(7):1064–72. - PubMed

MeSH terms